GLP-1 Receptor Agonists

Tirzepatide (GIP/GLP-1 Dual Agonist)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Tirzepatide (development code LY3298176) is a synthetic linear peptide that activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first-in-class unimolecular GIP/GLP-1 dual agonist and one of the most heavily published compounds in metabolic research. A fatty-diacid chain on a PEG linker lets it bind albumin, which stretches its half-life to about five days and supports once-weekly dosing in study protocols.

Chemical Profile

PropertyValue
CAS number2023788-19-2
Development codeLY3298176
ClassGIP / GLP-1 dual receptor agonist
Backbone39-amino-acid linear peptide with a C20 fatty-diacid moiety on a PEG linker
Molecular formulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight4813.45 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Tirzepatide at a glance
Class
GIP / GLP-1 dual agonist
Originator
Eli Lilly and Company
Research status
Extensive published literature
Study route
Subcutaneous, once weekly
Half-life
≈ 5 days
Key feature
First-in-class dual incretin agonist

Mechanism of Action

Tirzepatide engineers a single molecule to switch on two class-B G-protein-coupled receptors, GIPR and GLP-1R. Both couple through Gαs to raise intracellular cAMP, which drives the downstream signalling associated with incretin action. The fatty-diacid/PEG modification is not a signalling element — it binds albumin to slow clearance.

ComponentDetail
Primary targetsGIP receptor (GIPR) and GLP-1 receptor (GLP-1R)
Receptor classClass B G-protein-coupled receptors
G-protein couplingGαs → adenylyl cyclase → cAMP
Downstream signallingPKA, EPAC, CREB, PI3K/Akt pathways
β-arrestinRecruited — linked to receptor desensitization and internalization

Physiologic effects studied in the literature (research context, not clinical claims):

EffectStudied mechanism
Glucose-dependent insulin secretionGLP-1R activation in pancreatic β-cells
Glucagon suppressionGLP-1R activation in pancreatic α-cells
Delayed gastric emptyingVagal modulation via GLP-1R
Increased satietyGLP-1R and GIPR activation in the hypothalamus
Energy expenditure / lipid handlingGIPR activation in adipose tissue

Pharmacology

ParameterValue
Half-life (t½)≈ 5 days (~113–119 h)
Time to peak (Tmax)8–24 h post-dose
Bioavailability (SC)≈ 80%
Volume of distribution≈ 0.3 L/kg
Protein binding≈ 99% (albumin)
MetabolismProteolytic degradation (no CYP involvement)
EliminationRenal (peptide fragments) and fecal

Research Evidence

Tirzepatide has a large preclinical and clinical literature. The tables below name representative studies and trial programs and what they investigated; specific numerical outcomes are not restated here as claims.

Preclinical modelResearch focusReference
Diet-induced obese miceBody-weight and metabolic effects vs selective GLP-1 agonismCoskun T, et al. (2018)
High-fat-diet miceGlucose tolerance and lipid metabolismSamms RJ, et al. (2020)
Receptor pharmacologyBiased / imbalanced dual GIP/GLP-1 agonismWillard FS, et al. (2020)
Non-human primatesDose-dependent body-composition effectsUrva S, et al. (2020)
Clinical programPhaseResearch focusReference
SURPASS-1 … 4Phase 3Glycemic control in type-2-diabetes study populationsCoskun T, et al. (2018)
SURPASS-2Phase 3Head-to-head vs semaglutideFrías JP, et al. (2021), Lancet
SURMOUNT-1 / 2Phase 3Body-weight endpoints in obesity researchJastreboff AM, et al. (2022), NEJM

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Greater HbA1c reduction than semaglutide (head-to-head)SURPASS-2, type-2-diabetesFrías JP et al., Lancet 2021
Substantial body-weight reduction in obesitySURMOUNT-1Jastreboff AM et al., NEJM 2022
Dual GIP/GLP-1 exceeds selective GLP-1 in preclinical weight modelsdiet-induced obese miceCoskun T et al., 2018

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dosing range (literature)0.25–2.0 mg, once weekly (SC), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Reconstitution volume1–2 mL per vial
Final concentration≈ 2.5–5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~14 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.

CategoryPublished observations
Most commonGastrointestinal: nausea, diarrhea, vomiting, decreased appetite (dose-dependent)
Serious (rare)Pancreatitis, gallbladder-related events reported at low frequency
Rodent findingThyroid C-cell tumors in rodent studies; human relevance unconfirmed
InteractionsDelayed gastric emptying may affect absorption of co-administered oral compounds
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ 4.8
Isoelectric point (pI)≈ 5.0
pH (reconstituted)7.0–8.0
Appearance (solution)Clear, colorless
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Tirzepatide is assembled by solid-phase peptide synthesis, with the C20 fatty-diacid installed on a lysine side chain via a linker after selective side-chain deprotection. The long, highly charged sequence makes coupling efficiency and preparative purification the demanding steps.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinRink amide MBHA resin
CouplingHATU / HBTU with DIPEA (double couplings for hindered residues)
Fatty-acid conjugationC20 diacid coupled to a Lys side chain after selective (Mtt) deprotection
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, ACN/H₂O + 0.1% TFA gradient)
Salt exchangeLyophilization from dilute HCl (acetate → chloride)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. A large, highly charged peptide — deletion-peptide control is important.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 20–60% B over 25 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)
MALDI-TOFMass confirmation[M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 20–60% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)). A large, highly charged peptide — deletion-peptide control is important.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: A large, highly charged peptide — deletion-peptide control is important.

Selected References

  • Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Diabetes, 2018.
  • Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. Journal of Biological Chemistry, 2020.
  • Frías JP, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). The Lancet, 2021.
  • Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; endotoxin tested by LAL
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Tirzepatide — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote